Schizophrenia Therapeutics Market by Therapeutic Class (Second Generation, Third Generation), Administration (Injectable, Oral), Distribution Channel - Global Forecast 2024-2030

Schizophrenia Therapeutics Market by Therapeutic Class (Second Generation, Third Generation), Administration (Injectable, Oral), Distribution Channel - Global Forecast 2024-2030


The Schizophrenia Therapeutics Market size was estimated at USD 7.89 billion in 2023 and expected to reach USD 8.08 billion in 2024, at a CAGR 4.94% to reach USD 11.06 billion by 2030.

Global Schizophrenia Therapeutics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Schizophrenia Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Schizophrenia Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Schizophrenia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Acadia Pharmaceuticals Inc., Alkermes Plc, Allergan Plc by AbbVie Inc., Amneal Pharmaceuticals, LLC, Astellas Pharma Inc., AstraZeneca plc, BioXcel Therapeutics, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb and Company, Delpor, Inc., Eli Lilly and Company, Gedeon Richter Plc, Johnson & Johnson Services, Inc., Karuna Therapeutics Inc, Lundbeck A/S, Luye Pharma Group Ltd, Lyndra Therapeutics Inc, Meiji Holdings Co., Ltd., Neurocrine Biosciences, Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage



This research report categorizes the Schizophrenia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapeutic Class
Second Generation
Third Generation
Administration
Injectable
Oral
Distribution Channel
Hospital
Pharmacies
Offline
Online
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Schizophrenia Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Schizophrenia Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Schizophrenia Therapeutics Market?
4. What is the market share of the leading vendors in the Schizophrenia Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Schizophrenia Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Schizophrenia Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of schizophrenia disorder among individuals worldwide
5.1.1.2. Government initiatives and campaigns to raise awareness regarding mental health conditions
5.1.1.3. Ongoing research for the development of efficient drugs for schizophrenia
5.1.2. Restraints
5.1.2.1. High cost of treatment and lack of insurance coverage
5.1.3. Opportunities
5.1.3.1. Increasing focus on personalized medicine for improving drug efficacy in patients with schizophrenia disorder
5.1.3.2. Advancements in schizophrenia treatment and therapeutics
5.1.4. Challenges
5.1.4.1. Side effects associated with the medications prescribed for schizophrenia
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Schizophrenia Therapeutics Market, by Therapeutic Class
6.1. Introduction
6.2. Second Generation
6.3. Third Generation
7. Schizophrenia Therapeutics Market, by Administration
7.1. Introduction
7.2. Injectable
7.3. Oral
8. Schizophrenia Therapeutics Market, by Distribution Channel
8.1. Introduction
8.2. Hospital
8.3. Pharmacies
8.4.1. Offline
8.4.2. Online
9. Americas Schizophrenia Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Schizophrenia Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Schizophrenia Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Acadia Pharmaceuticals Inc.
13.1.2. Alkermes Plc
13.1.3. Allergan Plc by AbbVie Inc.
13.1.4. Amneal Pharmaceuticals, LLC
13.1.5. Astellas Pharma Inc.
13.1.6. AstraZeneca plc
13.1.7. BioXcel Therapeutics, Inc.
13.1.8. Boehringer Ingelheim International GmbH
13.1.9. Bristol-Myers Squibb and Company
13.1.10. Delpor, Inc.
13.1.11. Eli Lilly and Company
13.1.12. Gedeon Richter Plc
13.1.13. Johnson & Johnson Services, Inc.
13.1.14. Karuna Therapeutics Inc
13.1.15. Lundbeck A/S
13.1.16. Luye Pharma Group Ltd
13.1.17. Lyndra Therapeutics Inc
13.1.18. Meiji Holdings Co., Ltd.
13.1.19. Neurocrine Biosciences, Inc.
13.1.20. Otsuka America Pharmaceutical Inc.
13.1.21. Pfizer Inc.
13.1.22. Reviva Pharmaceuticals Holdings, Inc.
13.1.23. Sumitomo Dainippon Pharma Co., Ltd.
13.1.24. Takeda Pharmaceutical Company Limited
13.1.25. Vanda Pharmaceuticals Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SCHIZOPHRENIA THERAPEUTICS MARKET DYNAMICS
FIGURE 7. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 8. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings